The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
The clinical use of bleomycin is limited by a dose-dependent pulmonary toxicity. Bleomycin is thought to be growth inhibitory by virtue of its ability to oxidatively damage DNA through its complex with iron. Our previous preclinical studies showed that bleomycin-induced pulmonary toxicity can be reduced by pretreatment with the doxorubicin cardioprotective agent dexrazoxane. Dexrazoxane is thought to protect against iron-based oxygen radical damage through the iron chelating ability of its hydrolyzed metabolite ADR-925, an analog of ethylenediaminetetraacetic acid (EDTA). ADR-925 quickly and effectively displaced either ferrous or ferric iron from its complex with bleomycin. This result suggests that dexrazoxane may have the potential to antagonize the iron-dependent growth inhibitory effects of bleomycin. A study was undertaken to determine if dexrazoxane could antagonize bleomycin-mediated cytotoxicity using a CHO-derived cell line (DZR) that was highly resistant to dexrazoxane through a threonine-48 to isoleucine mutation in topoisomerase IIalpha. Dexrazoxane is also a cell growth inhibitor that acts through its ability to inhibit the catalytic activity of topoisomerase II. Thus, the DZR cell line allowed us to examine the cell growth inhibitory effects of bleomycin in the presence of dexrazoxane without the confounding effect of dexrazoxane inhibiting cell growth. The cell growth inhibitory effects of bleomycin were unaffected by pretreating DZR cells with dexrazoxane. These results suggest that dexrazoxane may be clinically used in combination with bleomycin as a pulmonary protective agent without adversely affecting the antitumor activity of bleomycin.
Wu
Xing
X
Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, Winnipeg, Manitoba, Canada R3T 2N2.
Patel
Daywin
D
Hasinoff
Brian B
BB
D000818:Animals; D001761:Bleomycin / Q000494:pharmacology*; D016466:CHO Cells; D002316:Cardiotonic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects*; D002614:Chelating Agents / Q000494:pharmacology*; D006224:Cricetinae; D006868:Hydrolysis; D007501:Iron / Q000494:pharmacology*; D007700:Kinetics; D008968:Molecular Conformation; D015394:Molecular Structure; D011929:Razoxane / Q000737:chemistry / Q000494:pharmacology*
D002316:Cardiotonic Agents; D002614:Chelating Agents; D001761:Bleomycin; D011929:Razoxane; D007501:Iron